MXPA01006377A - Administracion pulmonar de medicamento. - Google Patents

Administracion pulmonar de medicamento.

Info

Publication number
MXPA01006377A
MXPA01006377A MXPA01006377A MXPA01006377A MXPA01006377A MX PA01006377 A MXPA01006377 A MX PA01006377A MX PA01006377 A MXPA01006377 A MX PA01006377A MX PA01006377 A MXPA01006377 A MX PA01006377A MX PA01006377 A MXPA01006377 A MX PA01006377A
Authority
MX
Mexico
Prior art keywords
formulation
drug delivery
pulmonary drug
pulmonary
dispenser
Prior art date
Application number
MXPA01006377A
Other languages
English (en)
Inventor
Modi Pankaj
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of MXPA01006377A publication Critical patent/MXPA01006377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion farmaceutica en aerosol que comprende un agente farmaceutico proteinico, agua, un fenol y un propulsor. El fenol es fenol y/o fenol de metilo en una concentracion de uno a 10% p/p de la formulacion total. El propulsor es un eter dialquil C1- C2, butanos, propulsor de fluorocarbono, propulsor de fluorocarbono con contenido de hidrogeno, propulsor de clorofluorocarbono, o propulsor de clorofluorocarbono con contenido de hidrogeno o mezclas de los mismos. Opcionalmente, pueden estar presentes excipientes seleccionados del grupo consistente de sales, antioxidantes, agentes colorantes, agentes saborizantes, inhibidores de proteasa, estabilizadores, glicerina, poligricerina, lisina, polilisina y mezclas de los mismos. Preferentemente, la formulacion es administrada bucalmente, utilizando un abastecedor de dosis medida.
MXPA01006377A 1998-12-21 1999-12-16 Administracion pulmonar de medicamento. MXPA01006377A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11324398P 1998-12-21 1998-12-21
US09/397,102 US6294153B1 (en) 1998-12-21 1999-09-16 Aerosol pharmaceutical formulation for pulmonary and nasal delivery
PCT/CA1999/001232 WO2000037052A1 (en) 1998-12-21 1999-12-16 Pulmonary drug delivery

Publications (1)

Publication Number Publication Date
MXPA01006377A true MXPA01006377A (es) 2002-05-06

Family

ID=26810843

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01006377A MXPA01006377A (es) 1998-12-21 1999-12-16 Administracion pulmonar de medicamento.

Country Status (13)

Country Link
US (1) US6294153B1 (es)
EP (1) EP1143931B1 (es)
JP (1) JP3818852B2 (es)
AT (1) ATE341309T1 (es)
AU (1) AU759051B2 (es)
CA (1) CA2353847C (es)
DE (1) DE69933472T2 (es)
DK (1) DK1143931T3 (es)
ES (1) ES2274651T3 (es)
MX (1) MXPA01006377A (es)
NZ (1) NZ512272A (es)
PT (1) PT1143931E (es)
WO (1) WO2000037052A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6350432B1 (en) * 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
EP2325193A3 (en) 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003272970B2 (en) * 2002-10-11 2009-05-28 Sanwa Kagaku Kenkyusho Co. Ltd. GLP-1 derivatives and transmicosal absorption preparations thereof
WO2004044000A2 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
US20050153946A1 (en) * 2003-12-24 2005-07-14 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
ES2381201T3 (es) 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
US7846908B2 (en) * 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
US7812150B2 (en) 2006-05-19 2010-10-12 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
US8273770B2 (en) 2007-07-21 2012-09-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
WO2009100383A2 (en) 2008-02-07 2009-08-13 University Of Washington Circumferential aerosol device
AU2009232355A1 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of EPAS1 inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
US20130142868A1 (en) * 2010-08-20 2013-06-06 University Of Washington Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain
RU2728583C2 (ru) 2011-03-03 2020-07-30 Импел Ньюрофарма Инк. Устройство для назальной доставки лекарственных средств
RU2618084C2 (ru) 2011-05-09 2017-05-02 Импел Ньюрофарма Инк. Наконечники для назальной доставки лекарственных средств
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
US10537692B2 (en) 2013-04-28 2020-01-21 Impel Neuropharma, Inc. Medical unit dose container
US10004764B2 (en) 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
CA2998182A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma, Inc. In-line nasal delivery device
CA3081680A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
CA3087698A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
EP3735244B1 (en) 2018-01-05 2022-11-23 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
EP3768267A4 (en) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
CN112789037A (zh) 2018-09-06 2021-05-11 创新药物筛选有限公司 用于治疗哮喘或帕金森病的方法和药物组合物
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
KR20210109007A (ko) 2019-01-03 2021-09-03 임펠 뉴로파마 인코포레이티드 비강 약물 전달 장치
BR112021023049A8 (pt) 2019-05-17 2022-10-18 Impel Neuropharma Inc Dispositivo de dispensação nasal de uso único
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
EP0158441B2 (en) 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
ES2193186T3 (es) 1993-12-02 2003-11-01 Abbott Lab Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
WO1996040057A2 (en) 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Reverse fluorocarbon emulsion compositions for drug delivery
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Also Published As

Publication number Publication date
AU759051B2 (en) 2003-04-03
ATE341309T1 (de) 2006-10-15
AU1851900A (en) 2000-07-12
DK1143931T3 (da) 2007-02-12
DE69933472T2 (de) 2007-05-31
DE69933472D1 (de) 2006-11-16
PT1143931E (pt) 2007-01-31
CA2353847C (en) 2007-03-06
WO2000037052A1 (en) 2000-06-29
EP1143931B1 (en) 2006-10-04
JP3818852B2 (ja) 2006-09-06
EP1143931A1 (en) 2001-10-17
US6294153B1 (en) 2001-09-25
CA2353847A1 (en) 2000-06-29
JP2002532537A (ja) 2002-10-02
ES2274651T3 (es) 2007-05-16
NZ512272A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
MXPA01006377A (es) Administracion pulmonar de medicamento.
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
BR9912170A (pt) Inaladores de dose medida pressurizados e formulações de aerossóis farmacêuticas
MY131733A (en) Aerosol drug formulations
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
TR199701168T1 (xx) Flutikazon Propionat i�in �l��lm�� doz inhaleri.
TR199701169T1 (xx) Salmeterol i�in �l��lm�� doz inhaleri.
UY24813A1 (es) Nuevas preparaciones medicamentosas acuosas para la produccion de aerosoles libres de gas propulsor
GEP20063986B (en) Formoterol superfine formulation
YU56600A (sh) Uređaj za raznošenje aktivnog agensa u pluća pacijenta
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
EP1242013A4 (en) ORAL TRANSMUCOSAL GALENIC FORM USING SOLID SOLUTION
BG106221A (en) Morphine-containing intranasal pharmaceutical preparations and methods for their administration
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
YU8701A (sh) Nova oralna kompozicija
GB1114313A (en) Pharmaceutical compositions
US20100227008A1 (en) Salicylic acid acne spray formulations and methods for treating acne with same
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
EP1110547A3 (en) Helium and neon as means delivering drug in inhaler
DE60318182D1 (de) Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe
IL140839A0 (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis
GEP20053649B (en) Stable Pharmaceutical Solution Formulations for Pressurised Metered Dose Inhalers
MY152490A (en) New oral formulation

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees